A. Gringeri

Istituto Superiore di Sanità — Italy

Medicine · Health Sciences

53h-index9.2kcitations249works2.22yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hemophilia Treatment and Research(186), Platelet Disorders and Treatments(51), Blood Coagulation and Thrombosis Mechanisms(43), HIV Research and Treatment(28), Hepatitis C virus research(24)

Publications249 total

Launch of a National Registry for Congenital Hematological Disorders in Palestine: the Haemo-PAL Initiative
Bleeding Thrombosis and Vascular Biology·2026Open Access
The Humanitarian and Medical Crisis in Palestinian Territories: The Plight of Patients With Congenital Bleeding Disorders and Health Care Under Siege
Haemophilia·2026
Global estimation of the bleeding episodes treatable with desmopressin in von Willebrand disease and hemophilia A
Haematologica·2025· 1 citedOpen Access
The value‐based healthcare approach to haemophilia: Development of outcome measures for the evaluation of care of people with haemophilia
Haemophilia·2024· 3 citedOpen Access
New orphan disease therapies from the proteome of industrial plasma processing waste- a treatment for aceruloplasminemia
Communications Biology·2024· 7 citedOpen Access
PCR191 Assessing Quality of Care in Haemophilia Using a Value-Based Healthcare Approach
Value in Health·2023Open Access
ADAMTS13 levels in a plasma-derived FVIII concentrate: A potential therapeutic option for patients with congenital thrombotic thrombocytopenic purpura
Thrombosis Update·2022· 2 citedOpen Access
Adamts13 Levels in a Plasma-Derived Fviii Concentrate:  A Potential Therapeutic Option for Patients with Congenital Thrombotic Thrombocytopenic Purpura
SSRN Electronic Journal·2022· 1 citedOpen Access
Prophylactic bypassing agent use before and during immune tolerance induction in patients with haemophilia A and inhibitors to <scp>FVIII</scp>
Haemophilia·2018· 8 citedOpen Access
The multiple benefits of sport in haemophilia
Haemophilia·2018· 3 citedOpen Access
Comparative analysis of marketed factor VIII products: recombinant products are not alike vis‐a‐vis soluble protein aggregates and subvisible particles
Journal of Thrombosis and Haemostasis·2018· 8 citedOpen Access
Thromboembolic event rate in patients exposed to anti-inhibitor coagulant complex: a meta-analysis of 40-year published data
Blood Advances·2017· 12 citedOpen Access
Incidence of Thrombo-Embolic Events in Relation to Activated Prothrombin Complex Concentrate Exposure: A Literature Meta-Analysis
Blood·2017
Pattern of bleeding in a large prospective cohort of haemophilia A patients: A three‐year follow‐up of the <scp>AHEAD</scp> (Advate in HaEmophilia A outcome Database) study
Haemophilia·2017· 44 citedOpen Access
Meta-analysis on incidence of inhibitors in patients with haemophilia A treated with recombinant factor VIII products
Blood Coagulation & Fibrinolysis·2017· 24 cited
Current and future approaches to overcoming the challenges of hemophilia treatment personalization
Expert Opinion on Orphan Drugs·2017
Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement
Haemophilia·2017· 84 cited
Real World Prospective Data on Bleeding Frequency in 1,000 Patients with Hemophilia a - is the Goal of Zero Bleeds Achievable?
Haemophilia·2017· 4 cited
Target plasma factor levels for personalized treatment in hämophilia: a Delphi consensus statement
2017
Feiba Global Outcome Study (FEIBA-GO): Long-Term Real World Data on Apcc (FeibaR) in Patients with Inhibitors. First Demographic Data
Blood·2016
page 1 of 13Next →

Frequent Co-authors

Pier Mannuccio Mannucci(12), Elena Santagostino(11), LG Mantovani(7), Angiola Rocino(7), Jan Astermark(6), Massimo Morfini(6), Erik Berntorp(5), W. Schramm(5), Daniel Zagury(5), B Bizzini(5), Erik Berntorp(4), Claude Négrier(4), Jerzy Windyga(4), Jay Rappaport(4), Arsène Burny(4), Robert C. Gallo(4), M. Schiavoni(4), Bruce M. Ewenstein(4), Sylvia von Mackensen(3), L Scalone(3)